Friday, 17 Aug 2018

You are here

The RheumNow Week in Review – Modifiable Behavior (5.18.18)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis and modifiable behaviors that influence outcomes. 

  1. Osteoarthritis Initiative study of 1203 pts shows that running was not associated with worsening of knee pain or radiographic structural progression https://t.co/Y7UCTNMpKy
  2. Genentech announces that the FDA has approved Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis. https://t.co/E4z3K5LeBQ 
  3. RA pts have a greater risk of CVA; Study of 7904 RA pts shows that short-term (<7yrs) methotrexate might decrease ischemic stroke risk, but hydroxychloroquine and sulfasalazine did not. https://t.co/gRM9yrJOS0  RA 21% ^risk.
  4. Walmart (Sams) announced it is following CDC opioid prescribing recs and will soon limit initial opioid prescriptions to no more than seven days of supply, aiming avoid abuse https://t.co/uzn2xhbYL7
  5. UAB to lead the RECIPE trial in gout - a phase II trial to evaluate the utility of background mycophenolate (MMF) in patient receiving IV pegloticase injection for gout. Presumeably the MMF will block any interferring immunogenicity to PEG. https://t.co/ypBjwkeLpf
  6. Study of 148 SLE women shows obesity to be independently associated with worse disease activity, depressive symptoms, and symptoms of pain and fatigue. Obesity may be a modifiable target in SLE. https://t.co/XtrYr49msZ
  7. Lupus and diabetes have similar CVD risk; Claims data study of Medicaid pts shows SLE pts receive less lipids testing (66% less) & less likely to fill a statin Rx (82% less than DM; 11% less than Nl Pop) https://t.co/cjo4AtXHQs
  8. Opioid Marketing & Meals Tied to Opioid Prescribing  
  9. Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

ACR Meets With HHS Secretary Azar to Discuss Step Therapy Concerns

Yesterday, the American College of Rheumatology (ACR) met with U.S. Department of Health and Human Services Secretary Alex Azar for a productive discussion about the rheumatology community's concerns with a new policy that will allow Medicare Advantage plans to utilize step therapy in Medicare Part B. In the meeting, the ACR expressed concerns that this policy would delay rheumatology patients' access to treatments.

The RheumNow Week in Review – We’re Number One! (8.17.18)

Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.

U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.

The RheumNow Week in Review – No Good Gout (8.10.18)

Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

The RheumNow Week in Review – Handshakes or Hugs (8.3.18)

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com, including new treatments for LTBI, gout consequences, RA and offspring risk, PsA risk, and the opioid epidemic effects.